Yüklüyor......
Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma
AIMS: Medicare patients with metastatic or surgically unresectable urothelial carcinoma (mUC) often receive platinum-based chemotherapy as first line of therapy (LOT) but invariably progress, requiring additional LOTs and healthcare resource use (HCRU). To better understand the evolving mUC treatmen...
Kaydedildi:
| Yayımlandı: | J Med Econ |
|---|---|
| Asıl Yazarlar: | , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7384456/ https://ncbi.nlm.nih.gov/pubmed/30836812 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/13696998.2019.1591424 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|